Charged Alpha Stock Encyclopedia

Cummins Inc. (CMI) Q2 2026 — Reported Aug 4, 2026 pre-open for the quarter ended June 30, 2026. Revenue $9,457M, +9.4%, a Q2 record, BEATING the $9.31B consensus. Diluted EPS $6.73 vs $7.17 expected - a 6.1% MISS, the first in five quarters. EBITDA $1,653M, 17.5% of sales, DOWN from 18.4%. FY2026 revenue guidance RAISED to +10-13% from +8-11%. Prior close $648.85; the stock sat at $613.26 (-5.5%) when this episode was recorded.

Cummins posted a record quarter and RAISED guidance - and the stock fell 5.5% on a 44-cent EPS miss. Almost nobody reported that 43 of those 44 cents were a tax true-up and an incentive-compensation accrual, and that the accrual exists BECAUSE Cummins just guided to a record year. The operating business did not miss.

THE CALL: HOLD (3/5, THE MISS WAS NOISE - THE PRICE IS NOT) — base-case value ~$525.0 vs ~$613.26 today.

KEY METRICS:

- CALL: HOLD 3/5 - fair value ~$525 vs $613.26 (-14%). We are NOT bearish on this quarter; we think the tape misread it. We are bearish on the price the market was already paying - CMI DOUBLED in ten months into this print, from a $361.59 close on Aug 4 2025 to $727.59 on Jun 25 2026.

- THE MISS, LINE BY LINE: consensus $7.17, actual $6.73, gap $0.44. Company-stated: $29M / $0.21 per share of unfavourable DISCRETE TAX items (tax rate 25.1%); a year ago discrete items were FAVOURABLE by $0.02, so the YoY swing is $0.23. Our sizing of the incentive comp: SG&A $779M -> $893M, +14.6%, vs revenue +9.4%; at the revenue rate SG&A would be $852M, so $41M excess, $31M after tax = $0.22. $0.21 + $0.22 = $0.43 of $0.44.

- POWER SYSTEMS IS THE STORY: revenue $2,255M, +19%, with the power generation product line $1,205M -> $1,536M, +27%, on data centre demand in the US, China and Asia Pacific. Segment EBITDA margin EXPANDED 22.8% -> 24.5% while Engine (13.8->12.5), Components (14.7->13.2) and Distribution (14.6->13.6) all compressed. Power Systems is 24% of sales and 33% of segment profit. June deal: Circe Energy gensets for a Texas HPC microgrid, deliveries 2026-2030.

- THE GUIDE NEEDS A MARGIN INFLECTION: FY EBITDA guided 18.0-18.5% on revenue of $37.0-38.0B = $6,667-7,039M. H1 ex-specials was $3,142M on $17,855M (17.6%). That leaves $3,525-3,897M on $19.2-20.2B of H2 revenue - an 18.4% to 19.3% H2 margin, a 90-180bp step up from a first half that compressed. NOT A PRE-BUY: Engine North America grew just 1%; international grew 23% on Chinese construction. The NA growth came from Distribution (+13%) and Power Systems (+19%).

- VALUATION: base FCF $3.6B (H1 already $1,370M; below run-rate - CMI printed $2.75B FCF in 2023, $279M in 2024, $2.39B in 2025). Grow 8% five years, fade to 4%, 2.5% terminal, at 9%: EV $75,347M less $3,771M net debt = $71,576M / 138.5M diluted = $517; 25/50/25 weighting $523. Bear $305, bull $752. Reverse DCF: $613.26 needs ~11% FCF growth for five years - the Street's own EPS path ($29.28/$34.20/$40.61) clears that easily; it only fails if cash conversion stays at ~50% of EBITDA. VS THE STREET: Buy - 27 buy/23 hold/1 sell, 51 analysts - averaging $779.70 (high $901, low $600). They see +27%; we see -14%. We DIFFER and are more CAUTIOUS. CIK 0000026172.

What to watch: Bullish: a Q3 EBITDA margin at or above 18.4% - the low end of what the full-year guide mathematically requires - alongside continued Power Systems growth moves us toward $640. Bearish: Power Systems revenue growth decelerating below 10%, or Engine North America still flat in Q4, takes us to ~$400.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Spotify Technology S.A. (SPOT) Q2 2026 — Reported Aug 4, 2026 pre-open for the quarter ended June 30, 2026. Spotify REPORTS IN EUROS and TRADES IN DOLLARS, so every figure is labelled. Revenue EUR4,777M, +14% (+15% cc), in line with guide. Gross margin 33.4%, an all-time record. Operating income EUR655M vs a EUR630M guide - EUR655M, NOT the EUR762M some headlines used, which is the USD conversion. Diluted EPS EUR2.61 vs a EUR0.42 LOSS. Subscribers 300M (a BEAT); MAUs 777M (a MISS); ad revenue EUR446M, +1%. Prior close $486.33; the session opened $466.95 (-4.0%) then reversed to $499.64 (+2.7%).

Spotify announced 300 million subscribers - and ADVERTISING revenue grew ONE PERCENT, EUR440M to EUR446M, while the ad-supported audience grew 14% to 494M. Revenue per free listener fell ~11%, to about thirty euro cents a month. Two more nobody flagged: operating income rose 61%, but last year carried EUR115M of Social Charges - payroll taxes that move with the SHARE PRICE - against EUR1M now, so 46% of the gain is a falling stock; ex-charges profit grew 25.9% while costs grew 17.6%.

THE CALL: HOLD (3/5, FAIRLY PRICED - THE STREET'S NUMBER IS NOT) — base-case value ~$482.0 vs ~$499.64 today.

KEY METRICS:

- CALL: HOLD 3/5 - fair value ~$482 vs $499.64 (-3.5%), i.e. fairly valued. We are not bearish on Spotify; we are bearish on the STREET's $600.69. Built in EUROS, converted ONCE at EUR/USD 1.1527. Per-share figures come off the filing's EPS table (208,858,469 DILUTED) - vendor 'diluted EPS' for this issuer returns the BASIC number.

- VALUATION: owner FCF = EUR3,261M LTM reported FCF, LESS ~EUR400M for cash taxes converging on book (H1 paid EUR121M on a EUR391M charge), LESS ~EUR300M share-based pay = ~EUR2,500M. Grow 15/14/13/12/10%, fade to 5%, 3% terminal, at 8.75%: EV EUR78,345M + EUR9,000M net cash = EUR87,345M / 208.9M = ~$482. Bear $305, bull $699. KEY TEST: the IDENTICAL model on the UNADJUSTED EUR3,261M returns $614 - which IS the consensus.

- ADVERTISING: EUR446M, +1% (+3% cc), while ad-supported MAUs grew 14% to 494M. Revenue per ad listener fell ~11%, EUR1.02 to EUR0.90 a quarter - thirty euro cents per free listener per month. Spotify added 61M free users and collected six million euros for them. Ads are 9.3% of revenue, down from 10.5%, at a 19.1% gross margin vs 34.9% in Premium.

- MILESTONE AND GUIDE: subscribers beat while MAUs missed - the paid base overshot as the free funnel undershot, on 'strong global promotional campaign intake' and a 20th-anniversary campaign driving 'our single biggest day of new subscribers ever'. Premium ARPU EUR4.89, +7%, on price rises. Q3 guide: revenue EUR5.0B but assuming a ~200bps FX TAILWIND; gross margin 32.9%, DOWN from the record; operating income EUR670M = a 13.4% margin vs 15.8% in Q1.

- VS THE STREET: Buy - 32 buy / 18 hold / 2 sell across 52 analysts - averaging $600.69 (high $720, low $420); Morgan Stanley $640 Overweight. They see +20%; we see -3.5%. We DIFFER and are more CAUTIOUS - but do NOT dispute the milestone, the record margin or the EUR3.3B trailing FCF. SOURCING: CIK 0001639920 verified on EDGAR (6-K accession 0001140361-26-031044).

What to watch: Bullish: ad revenue back to double-digit cc growth for two straight quarters moves us toward $570. Bearish: a THIRD quarter of margin guided down while the spend is still called temporary, or Premium ARPU growth under 3%, takes us to ~$385.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Entegris, Inc. (ENTG) Q2 2026 — Reported August 4, 2026 BEFORE the US open for the fiscal second quarter ENDED JUNE 27, 2026 (a 13-week quarter - not June 30). Revenue $883.2M, +11.5% YoY and +8.8% sequential, beating the ~$835.8M FactSet consensus by $47.4M or 5.7%. Non-GAAP diluted EPS $0.93 vs $0.66 (+40.9%); GAAP EPS $0.61 vs $0.35 (+74.3%). GAAP gross margin 47.6% (+320bps), GAAP operating margin 18.6% (+520bps), adjusted operating margin 24.5% (from 20.9%), adjusted EBITDA margin 28.4%. Segments: Advanced Purity Solutions $514.6M (+17.0%, adj. margin 30.3% from 24.1%); Materials Solutions $371.3M (+4.6%, adj. margin 20.9% DOWN from 21.3%). Q3 2026 guidance: sales $905-935M (midpoint +14.0% YoY), non-GAAP EPS $0.96-1.04, adjusted EBITDA margin 28.0-29.0%. NO full-year guidance was given. Shares closed the prior regular session at $125.20 (+5.17%) BEFORE the release; the reaction session had not closed when this episode was recorded, with ENTG trading up roughly 8.6% at $135.92. The stock is 32% below its $184.00 closing high of June 22, 2026 and 82% above its $68.80 closing low of November 20, 2025.

The fact that makes this quarter interesting: Entegris now reports TWO segments, not the three most write-ups still use. Materials Solutions - the CMP slurries, deposition chemistries and implant gases that a wafer consumes whether or not anybody buys a tool, and therefore the segment that IS the content-per-wafer thesis - grew 4.6% with its adjusted margin going DOWN, to 20.9% from 21.3%. Advanced Purity Solutions, which sells into fab construction and expansion as well as production, grew 17.0% with its adjusted margin up 620 basis points to 30.3%. The secular half is the laggard; the cyclical half carried the print. Across five quarters Materials Solutions has gone $341M, $355M, $349M, $362M, $351M, $371M - nine percent of growth in the strongest capital cycle since 2021. Two more things almost nobody flagged. FIRST, the depreciation line fell $16.9M year over year (from $51.3M to $34.4M, -33%) while operating income rose $58.5M - so 29% of the entire operating profit increase is a non-cash accounting tailwind, not operating leverage. SECOND, first-half R&D was CUT 6.5% to $158.1M (10.8% of sales down to 9.3%) while SG&A rose 11.8%, in a company whose thesis is a strong innovation engine winning content at advanced nodes.

THE CALL: AVOID (3/5, A REAL RECOVERY, ALREADY PAID FOR TWICE OVER) — base-case value ~$95.0 vs ~$125.2 today.

KEY METRICS:

- CALL: AVOID 3/5 - fair value ~$95 vs the $125.20 close (about -24%), and below the LOWEST price target on Wall Street ($115). This is NOT a call against the business or the quarter, both of which were good; it is a call on a share price that ran 167% (from $68.80 on Nov 20 2025 to $184.00 on Jun 22 2026) BEFORE these numbers arrived. We value the ENTERPRISE because debt is a third of the story. Base unlevered free cash flow = ~$540M FY2026E reported FCF (H1 actual was $263.8M) plus ~$155M of after-tax net interest less ~$45M for a cash tax rate normalising from H1's 8.6% toward the 16.2% non-GAAP rate = ~$650M. Grow that 17%/14%/12%/10%/9%, then 6% for five more years, then 3% forever, discounted at 9.25% for a business carrying 3.35x net leverage into a cyclical end market: PV of 2027-2036 FCF $7,084M + PV of terminal value $10,600M = enterprise value $17,685M, less $3,102M net debt = $14,582M equity / 153.6M diluted shares = ~$95. Bear $46, bull $129; probability-weighted 25/50/25 = ~$91.

- REVERSE DCF - THE WHOLE ARGUMENT: at $125.20 the market capitalisation is ~$19.2B and enterprise value ~$22.3B - 24.1x trailing adjusted EBITDA of $925.6M and 34.4x our $650M base cash flow. To justify that at 9.25% you need roughly 16% unlevered free cash flow growth for five years and then 9%. The Q3 guide implies +14% revenue at the hottest point of the cycle, and the segment that is supposed to deliver the secular growth grew 4.6%. Note the robustness check: even at a friendly 8.5% discount rate our base case is only $112 - still BELOW the price. You have to move to the bull case to justify $125.20, which means the market is paying our bull case today, in cash.

- THE TWO HALVES (the reason for the call): Advanced Purity Solutions - filtration, purification, contamination control - did $514.6M, +17.0%, with adjusted segment margin at 30.3% from 24.1% (+620bps). Materials Solutions - the CMP slurries, deposition and etch/clean chemistries and implant gases that ARE the content-per-wafer story - did $371.3M, +4.6%, with adjusted segment margin at 20.9%, DOWN from 21.3%. APS now carries 58% of sales and 67% of adjusted segment profit. NOTE THE SEGMENT STRUCTURE: Entegris says it 'currently operates in two segments'. The old three-segment split (Materials Solutions / Microcontamination Control / Advanced Materials Handling) is STALE - MC and AMH were combined into APS in an internal reorganisation named in the restructuring footnote.

- WHERE THE PROFIT GROWTH CAME FROM: GAAP operating income rose $58.5M (from $106.1M to $164.6M). Over the same period the depreciation line fell $16.9M, from $51.3M to $34.4M, a 33% drop - so 29% of the entire increase in operating profit is a lower non-cash charge, not operating leverage. First-half depreciation fell $32.7M (from $101.2M to $68.5M). Separately, first-half engineering/R&D was CUT 6.5% to $158.1M from $169.1M - 10.8% of sales down to 9.3% - while SG&A rose 11.8% to $244.1M. In fairness the tax line cuts the company's way: GAAP net income grew 77.3% DESPITE the tax rate going from 5.0% to 15.0%, i.e. $13.7M more tax paid.

- CASH, CAPEX AND THE DELEVERAGING (the part that genuinely worked): Q2 free cash flow $120.3M vs $47.0M a year ago; H1 free cash flow $263.8M vs roughly $79M. The mechanism is capex falling off a cliff - H1 capex $80.8M vs $174.5M, down 54%, from 8.4% of sales to 4.4%, as the big fab build completes. Understand that is a ONE-TIME step down in spending, not a repeatable growth engine. Long-term debt $3,456.0M (from $3,987.8M a year ago) less $353.6M cash = $3,102M net debt, $508.6M retired in a year, taking leverage from about 4.1x to 3.35x trailing adjusted EBITDA. The gap: there were NO share repurchases at all, and diluted shares ROSE 1.1% to 153.6M. Dividend $15.4M/quarter, a 0.32% yield.

- GUIDANCE AND WHAT IS MISSING: Q3 2026 sales $905-935M (midpoint +14.0% vs 3Q25's $807.1M, +4.2% sequential), GAAP EPS $0.75-0.83, non-GAAP EPS $0.96-1.04, adjusted EBITDA margin 28.0-29.0%. There is NO full-year 2026 guidance - no annual revenue range, no annual EPS range, no capex number, no free cash flow target. Inside the ninety days, non-GAAP operating expense is guided from $203.9M to $211-219M: +5.4% cost against +4.2% sales, so costs are guided to grow FASTER than revenue next quarter.

- WHY WE ARE BELOW THE STREET: consensus is Buy - 17 buy / 8 hold / 1 sell across 26 analysts - at an average target of $165.43, high $205, low $115. Cross-checked against individual notes: Mizuho $200 (Outperform), BMO $167 (Outperform), Deutsche Bank $155 (Hold). The Street sees +32% upside; we see -24% downside, and even the most bearish Street target sits 21% ABOVE our fair value. We DIFFER and are far more CAUTIOUS - but note WHERE: we do NOT dispute the 5.7% revenue beat, the 360bps of adjusted operating margin expansion, the tripled free cash flow or the cycle. The disagreement is entirely the reverse DCF. Sourcing note: CIK 1101302 was verified independently on EDGAR, and both the EX-99.1 press release and the EX-99.2 earnings deck (accession 0001101302-26-000146) were grepped for 'Entegris' (32 and 18 hits) and the period before a single number was read off them. The quarter ENDED JUNE 27, 2026, not June 30.

What to watch: Bullish: Materials Solutions growing above 10% year on year WITH its segment margin expanding rather than contracting - that is the content-per-wafer thesis finally landing in the segment that carries it. Two consecutive quarters of that and our number moves toward $120. Bearish: capex re-accelerating toward 8% of sales while Materials Solutions stays in the low single digits, which would say the fab build is a treadmill rather than a finished project; or a buyback announced before leverage is under 3x. Another year of cutting R&D takes our number to roughly $75.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

IDEXX Laboratories, Inc. (IDXX) Q2 2026 — Reported August 4, 2026 BEFORE the US open for Q2 2026 (the quarter ended June 30, 2026). Revenue $1,216.6M, +9.7% reported and +9.0% organic, vs a ~$1.20B consensus. Diluted EPS $4.27, +17.6%, vs a $3.96 consensus - but $0.14 of that came from share-based-compensation tax benefits and $0.06 from currency. Gross margin 64.0% (+140bps reported, +120bps comparable); operating margin 35.0% (+140bps reported, +110bps comparable). CAG revenue $1,118.2M (+9.4%), CAG Diagnostics recurring revenue $974.7M (+11.0% reported, +10.3% organic), Water $58.6M (+14.8%), LPD $35.2M (+10.8%). Full-year 2026 guidance RAISED: revenue $4,700-4,745M (organic growth 8.5-9.7%, up from 7.7-9.7%), operating margin 32.3-32.5%, EPS $14.69-14.94 (from $14.45-14.90). Shares closed the prior regular session at $567.84 (+1.57%) BEFORE the release; the reaction session had not closed when this episode was recorded, with IDXX trading up roughly 3.5% in the pre-market. The stock is 26% below its $766.68 closing high of November 25, 2025 and 8% above its $526.44 closing low of June 30, 2026, and sits below its $620.50 two-hundred-day average.

The fact that makes this quarter interesting: US same-store veterinary clinical visits have been FALLING for about three years - roughly -1.9% across 2025 and about -1% in Q1 2026 - yet IDEXX's US CAG Diagnostics recurring revenue grew 9.7% organically to $630.5M. That is an ~11 percentage point gap between the end market's foot traffic and this company's revenue, and the whole investment case lives inside it. We went looking for the obvious explanation - that it is just price - and the evidence says mostly NOT: VetLab consumables grew 13.6% organically on stated VOLUME gains and an 11% larger global premium instrument installed base, and reference lab grew 10.3% organically on higher testing volumes and net new customers. Only rapid assay, at +1.1%, is a price story - and that one is self-inflicted, with volumes cannibalised by IDEXX's own Catalyst Pancreatic Lipase test. Two more things almost nobody flagged. FIRST, the $0.31 EPS beat is really about $0.11 of operations: $0.14 was share-comp tax benefits and $0.06 currency, both disclosed in the release. SECOND, forward free cash flow is LOWER than trailing free cash flow - capex steps from ~$117M trailing to a guided ~$180M, which is why the company guides FCF to 90-100% of net income against the 110% it just delivered.

THE CALL: AVOID (3/5, AN ELITE BUSINESS AT A PRICE THAT NEEDS PERFECTION) — base-case value ~$465.0 vs ~$567.84 today.

KEY METRICS:

- CALL: AVOID 3/5 - fair value ~$465 vs the $567.84 close (about -18%), and below the LOWEST price target on Wall Street ($620). This is NOT a criticism of the business, which is outstanding; it is a call on the price of entry. Base free cash flow is taken from the company's OWN guidance rather than from trailing results: FY2026 EPS of $14.82 at midpoint on ~79.4M shares is ~$1,176M of net income, and IDEXX guides FCF to 90-100% of net income = ~$1,117M. Grow that 11% a year for five years (ABOVE the 8.5-9.7% organic revenue guide, crediting 70-90bps of annual margin expansion plus a 1.5-2% buyback), then 7% for five more, then 3% forever, discounted at 8%: PV of 2027-2036 FCF $12,303M + PV of terminal value $25,201M = enterprise value $37,503M, less $772M net debt = $36,731M equity / 78.95M shares = ~$465. Bear $343, bull $590; probability-weighted 25/50/25 = ~$478.

- REVERSE DCF - THE WHOLE ARGUMENT: at $567.84 the market capitalisation is ~$44.8B and enterprise value ~$45.6B - 40.8x FY2026E free cash flow of $1,117M, a 2.5% FCF yield, and 38.3x guided FY2026 EPS. To justify that at an 8% discount rate you need roughly 14% free cash flow growth for five years and then 10%. IDEXX itself guides 8.5-9.7% ORGANIC REVENUE growth and 12-14% EPS growth - and that EPS figure already contains 1.5-2% of share-count reduction. The market is therefore pricing an acceleration above what the company guides, with no discount for the possibility that utilisation growth decays as penetration matures.

- THE DECOUPLING (the reason to own it): US CAG Diagnostics recurring revenue $630.5M, +9.7% organic, against US same-store clinical visits running roughly -1 to -2%. International CAG Diagnostics recurring +13.6% reported / +11.6% organic off a far lower penetration base. Mechanism, not price: IDEXX VetLab consumables $430.3M (+14.7% reported, +13.6% organic) on testing utilisation gains, new product launches, net new customers and an 11% expansion of the global premium instrument installed base; reference laboratory diagnostic and consulting services $406.7M (+10.6% reported, +10.3% organic) on higher testing volumes. IDEXX inVue Dx installed base surpassed 9,000 instruments with over 1,600 placements in the quarter.

- THE RAZOR-AND-BLADE MATH: of $1,118.2M of CAG revenue, $974.7M is CAG Diagnostics recurring and $76.3M is recurring veterinary software - so ~94% of companion animal revenue is RECURRING. CAG capital instruments were only $47.2M, 4.2% of the segment. So the headline 'instrument sales fell 19.5%' is an $11.4M decline inside a $1,216.6M quarter, under 1% of the company, and the release attributes it to lapping the Q2 2025 broad availability of inVue Dx. The one genuinely soft line is rapid assay products: $101.6M, +1.3% reported and +1.1% organic, driven by NET PRICE with volumes pressured by adoption of IDEXX's own Catalyst Pancreatic Lipase Test.

- MARGIN AND SEGMENT DETAIL: gross profit $779.1M at 64.0% (from 62.6%); total operating expense $353.5M (+9.9%, roughly in line with revenue) split S&M $171.3M, G&A $116.8M, R&D $65.4M; income from operations $425.6M at 35.0% (from 33.6%). Net income $338.4M; diluted shares 79,312K, down 2.1% from 80,994K. By segment: CAG operating income $393.3M at 35.2% (from 34.1%); Water revenue $58.6M at a 74.4% gross margin and 51.7% operating margin; LPD $35.2M at a 53.0% gross margin, swinging to a $2.4M operating profit from a $0.5M loss a year ago. Note margin seasonality - Q2 printed 35.0% against a full-year guide of 32.3-32.5%.

- CASH, CAPEX AND THE BUYBACK: Q2 free cash flow $322.5M (more than double the $151.6M of a year ago); H1 free cash flow $556.8M vs $359.6M, from $613.4M of operating cash flow less $56.6M capex. Trailing twelve months: ~$1,372M operating cash flow less ~$117M capex = ~$1,255M FCF on ~$1,140M net income, 110% conversion. BUT 2026 capex is guided to ~$180M, so ~$123M lands in H2 - which is why FY2026 FCF is guided to just 90-100% of net income. Buybacks: 1,170K shares repurchased in the open market in H1 for $692.9M at an average of $592.41 (Q2 alone 582K shares at $570.72) - ABOVE the $567.84 close. The revolver rose from $398M to $519M; total debt $968.9M less $196.9M cash = $772M net debt against $1,612.6M of equity.

- WHY WE ARE BELOW THE STREET: consensus is Buy - 13 buy / 8 hold / 1 sell across 22 analysts with live targets - at an average target of $723.33, median $750, high $800, low $620. The Street sees +27% upside; we see -18% downside. We DIFFER and are far more CAUTIOUS - but note WHERE: we do NOT dispute the franchise, the moat, the 64% gross margin, or the decoupling from visit volumes, and we modelled FCF growth ABOVE the company's own organic revenue guidance. The disagreement is entirely the reverse DCF. Note also that the brief for this episode listed CIK 832988 for IDEXX - that is SIGNET JEWELERS; the correct IDEXX CIK is 874716, and every figure here was read off the 8-K EX-99.1 filed under accession 0001104659-26-090033 after grepping it for the company name and the period.

What to watch: Bullish: CAG Diagnostics recurring organic growth HOLDING double digits into 2027 while US clinical visits stabilise rather than fall. If visits merely stop shrinking our growth assumption is too low and fair value moves toward $560. Bearish: recurring organic growth decaying below 7% as premium-instrument penetration matures while capex stays at the new ~$180M level - that takes free cash flow growth into the high single digits and our number to roughly $390. Also watch the buyback price: $692.9M was spent in H1 at an average of $592.41, above where the stock trades today.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Ultra Clean Holdings, Inc. (UCTT) Q2 2026 — Reported August 3, 2026 after the US close for Q2 2026 (the quarter ended June 26, 2026). Revenue $644.9M (+24.3% YoY, +20.8% QoQ) vs a $587.6M consensus and the company's own $565-605M guidance - a beat above the TOP END. Products $572.7M (+25.9%), Services $72.2M (+13.0%). GAAP gross margin 16.1%, operating margin 4.6%, net income attributable to UCT $8.7M or $0.19/sh. Non-GAAP gross margin 16.7%, operating margin 7.0%, net income $32.3M or $0.70/sh vs a $0.531 consensus. Q3 2026 guidance: revenue $700-750M (+12% QoQ at the midpoint, +42% YoY), GAAP EPS $0.67-0.87, non-GAAP EPS $0.83-1.03. Shares closed the regular session at $89.17 (+7.0%) BEFORE the release; the reaction session had not opened when this episode was recorded, and UCTT traded around $96.84 in the pre-market, about +8.6%. The stock is up more than 300% from its $21.63 low of August 6, 2025 and 37% below its $142.59 high of June 30, 2026.

The line nobody printed: revenue grew 24% and free cash flow was MINUS $100.2M. First-half operating cash flow was -$74.4M against +$57.4M a year ago - a $131.8M swing - and capex took another $25.8M. The bridge is one line: inventories consumed $238.9M of cash, with the balance going from $390.9M in December to $629.9M in June, roughly 106 days on hand against ~83 at year end. Accounts payable gave back $104.4M, so part of the build is being funded by stretching suppliers. Two more things nobody flagged. FIRST, the refinancing is doing about 40% of the earnings growth: interest expense fell to $1.1M from $10.1M after March's $600M 0.00% convertible notes replaced $481.5M of bank debt - roughly $0.16/sh after tax out of a $0.37 YoY improvement in non-GAAP EPS - and those notes convert at $84.75, below the $89.17 close, carrying 7.1M shares or 15.4% dilution. SECOND, the Q3 guide implies a GAAP-to-non-GAAP gap of just $0.16 against $0.51 this quarter; intangible amortisation alone is $0.15/qtr, so the US tax valuation allowance drag has to essentially vanish - a one-time, non-cash benefit, not earnings power.

THE CALL: AVOID (3/5, A GREAT QUARTER AT A PRICE WE CANNOT UNDERWRITE) — base-case value ~$62.0 vs ~$89.17 today.

KEY METRICS:

- CALL: AVOID 3/5 - fair value ~$62 vs the $89.17 close (about -30%), and below the LOWEST price target on Wall Street ($70). This is not a call on the business, which is executing; it is a call on the price of entry. DCF on free cash flow AFTER charging stock-based compensation as a real cost: revenue from ~$2.67B (2026E) to $3.81B by 2031, non-GAAP operating margin 7.0% -> 9.0%, SBC ~$36M growing 5%/yr, capex 2.6% of revenue vs D&A 1.9%, and working capital taking 20 cents of every incremental revenue dollar. At 10.5% and 2.5% terminal growth: PV of 2027-2031 FCF $476M + PV of terminal value $1,444M = EV $1,920M, less $343.5M net debt and $77.3M of noncontrolling interests, / 46.1M diluted shares = $32.52. Bear $12.20, bull $58.51; probability-weighted 25/50/25 = ~$34. We carry ~$62 because semi-cap is priced on mid-cycle earnings multiples, not on DCF: $3.25 of mid-cycle non-GAAP EPS at 18x is $58.50, and $5.00 of peak 2027 EPS at 16x is $80.

- REVERSE DCF - THE WHOLE ARGUMENT: at $89.17 the market capitalisation is $4.11B on 46.1M diluted shares and enterprise value is $4.53B - 1.69x revenue and 24.5x our FY2026 non-GAAP operating income estimate of $185M. Growth does NOT close the gap: we tested a 20% five-year revenue CAGR and the model still prints $28, because every incremental dollar of revenue drags ~20 cents of working capital with it. What $89.17 requires is a terminal OPERATING margin near 17% - against a GROSS margin of 16.7%. The discounted cash flow cannot get there at all, at any discount rate: even at an implausibly generous 7.5%, the base case is under $60.

- THE CASH: first-half operating cash flow -$74.4M (vs +$57.4M a year ago) less $25.8M capex = -$100.2M of free cash flow, against +$28.2M in the same half of 2025. Inventories consumed $238.9M; the balance rose from $390.9M (12/26/25) to $629.9M (6/26/26), about 106 days of cost of revenue vs ~83 at year end. Accounts payable +$104.4M. Cash fell from $311.8M to $255.9M despite raising $600M of converts. For every $1 of gross profit earned in the half, UCT put roughly $2 of parts on a shelf.

- THE BALANCE SHEET: $600M of 0.00% convertible senior notes due March 15, 2031 issued March 3, 2026 (net proceeds ~$583.3M), used to repay $481.5M of bank debt. Cash $255.9M, long-term debt $599.4M, NET DEBT $343.5M - about 1.5x annualised Q2 non-GAAP EBITDA. This is NOT a net-cash balance sheet. Conversion price $84.75/sh (11.80 shares per $1,000, a 42.5% premium to the $59.47 close of 2/26/26) - the $89.17 close is ABOVE it, so the notes are in the money; full conversion is 7.1M shares, 15.4% of the diluted count. $25.1M was paid for capped calls. The February 2026 Ninth Amendment temporarily raised the permitted gross leverage covenant to 6.00x for the March and June 2026 periods. Interest expense $1.1M vs $10.1M a year ago.

- CUSTOMER CONCENTRATION AND GEOGRAPHY (Q1 2026 10-Q, the most recent disclosure): Lam Research 36.7% of revenue and Applied Materials 21.8% = 58.5% from two customers. Lam, Applied and ASM International were each over 10% of gross receivables, ~39% in aggregate. Revenue shipped to China was only $24.8M, 4.6% of the total, and DOWN from $33.3M a year earlier - the direct China exposure is small, but the indirect exposure through Lam's and Applied's own China business is not. Singapore $203.2M (38%), United States $129.4M, Austria $57.2M, South Korea $28.2M, Malaysia $24.8M, Taiwan $16.6M.

- SEGMENTS AND MARGIN STRUCTURE: Products $572.7M (89% of revenue) at a 14.6% GAAP gross margin and 4.3% segment operating margin; Services $72.2M (11%) at a 27.4% gross margin and 6.6% operating margin - the small segment is nearly twice as profitable, and it is growing at 13% while the low-margin half grows at 26%. Non-GAAP operating income went from $27.1M (Q1) to $45.1M (Q2) on $111.2M of incremental revenue - a 16.2% INCREMENTAL operating margin, our math. GAAP effective tax rate 60.3% because US losses carry a full federal and state valuation allowance (non-GAAP rate 20%); that item alone is $0.26 of the $0.51 gap between $0.19 GAAP and $0.70 non-GAAP EPS. A year ago this quarter UCT wrote off $151.1M of goodwill; $114.2M remains.

- WHY WE ARE BELOW THE STREET: consensus is Buy - 8 buy / 4 hold / 0 sell across 12 analysts with live targets - at an average target of $103.75, median $107.50, high $130, low $70. Recent moves: TD Cowen to $130 (July, from $100), UBS initiating at $130 (May), Oppenheimer $115 (June, from $100), Needham $92 (from $70). The Street sees +16% upside; we see -30% downside. We DIFFER and are far more CAUTIOUS - but note WHERE: we are not arguing with the revenue. The WFE upcycle and the AI datacenter capex driving it are real, and the Q3 guide is real. We are arguing with the margin, the customer concentration and the cash conversion. SHARE COUNT read off the press release EPS table: 45.1M basic / 46.1M diluted.

What to watch: Bullish: operating cash flow turning sharply positive in Q3/Q4 as the $239M inventory build converts, which would prove it was pre-positioning rather than a pull-in; or non-GAAP gross margin clearing 18% and holding. Either moves our number toward $80. Bearish: Q3 revenue landing at the low end of the $700-750M guide with inventory still rising, or the Products gross margin slipping back under 14% as Lam and Applied press on price. Either takes us closer to $45.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Grab Holdings Limited (GRAB) Q2 2026 — Reported August 3, 2026 after the US close for Q2 2026 (the quarter ended June 30, 2026). Revenue $997M (+22% YoY, +21% constant currency) vs ~$990.4M expected. Adjusted EBITDA $168M (+54%), margin 16.9% from 13.3% - an 18th consecutive quarter of adjusted EBITDA growth. EPS $0.06 vs a $0.01 consensus. Profit for the period $235M vs $20M. On-demand GMV $6.5B (+21%); MTUs a record 54 million. FY2026 guidance RAISED at both ends: revenue to $4.10-4.15B (from $4.04-4.10B) and adjusted EBITDA to $720-740M (from $700-720M). New $750M buyback authorised, taking cumulative authorisations to $1.75B since 2024. Shares closed the regular session at $3.67 (+4.9% into the print) and traded up a further 4.1% after hours to about $3.82; the reaction session had not opened at publication. The stock is still ~43% below its $6.45 close of September 22.

The line nobody printed: Grab's record $235M profit is almost entirely accounting. Operating profit was $19M - a 1.9% margin on $997M of revenue. The gap is a $307M one-time gain on consolidating Superbank plus a $66M deferred-tax credit, less a $183M larger fair-value loss on the convertible notes; management called the Superbank gain 'one-time in nature' themselves. Meanwhile adjusted EBITDA rose 54% but operating cash flow FELL to $56M (-$8M YoY) and adjusted free cash flow fell to $73M (-$39M YoY): cash conversion went from ~103% of adjusted EBITDA a year ago to 43%. And in Mobility, transactions grew 28% while GMV grew 18% and revenue grew just 12% - a take rate down roughly 90bps to 14.9% as on-demand incentives rose 72bps to 10.9% of GMV. Grab is buying volume through a fuel crisis. Separately, the gross loan portfolio TRIPLED to $2.3B and $2.5B of digibank customer deposits now sit inside the $7.4B 'gross cash liquidity' - depositors' money, not shareholders'.

THE CALL: BUY (3/5, CHEAP - JUST NOT AS CHEAP AS THE STREET SAYS) — base-case value ~$4.6 vs ~$3.67 today.

KEY METRICS:

- CALL: BUY 3/5 - fair value ~$4.60 vs the $3.67 close (+25%), and ~+20% vs the $3.82 after-hours print. DCF on free cash flow AFTER charging share-based compensation as a real cost: revenue from the $4.125B 2026 guidance midpoint to $8.65B by 2031, adjusted EBITDA margin 17.7% -> 24%, less SBC at 6% of revenue fading to 3.5%, capex 4%, cash tax 20%. Free cash flow $0.38B (2027) rising to $1.12B (2031). At an 11% discount rate and 3% terminal growth: PV of 2027-2036 FCF $5.66B + PV of terminal value $7.24B = EV $12.90B, PLUS $5.40B of net cash liquidity, / 4.098B shares (Class A + Class B) = $4.47/sh. Bear $2.86, bull $6.22; probability-weighted 25/50/25 = $4.50. We sit at ~$4.60, a shade above the weighted case, for the $750M buyback executing below fair value.

- REVERSE DCF: at $3.67 the market capitalisation is $15.0B and enterprise value ~$9.6B - 13x this year's guided adjusted EBITDA and 2.3x revenue. At an 11% discount rate with 3% terminal growth, that price only asks Grab to grow revenue about 11% next year, fading to 5%. It just grew 22% and guided to 21%. That gap is the entire bull case.

- WHY WE ARE BELOW THE STREET: the consensus target is $5.63 across 12 analysts with live targets (11 buy / 0 hold / 1 sell, range $5.00-$6.25), and $5.88 across the wider 26-analyst panel. To justify $5.88 at an 11% discount rate you need Grab to compound revenue near 23%, fading to 10%, reaching roughly $19B by 2036 - a decade of near-flawless execution across eight emerging markets, through an oil shock, Indonesian regulation, and a loan book that has never seen a downturn. We ALIGN on the rating and are far more CAUTIOUS on the number.

- SEGMENTS (Q2 2026 revenue, with our year-ago derivation from the stated growth rates): Deliveries $531M (+21% from $439M), segment adjusted EBITDA 2.3% of GMV from 1.8%; Mobility $331M (+12% from $296M), segment adjusted EBITDA 8.6% of GMV, -9bps; Financial Services $134M (+59% from $84M), segment adjusted EBITDA -$15M from -$26M; Others ~$1M. Deliveries GMV $4,249M (+24% cc), Mobility GMV $2,214M (+18%). Our segment bridge: of the $59M adjusted EBITDA improvement, Deliveries supplied roughly $36M, Mobility ~$27M and Financial Services ~$11M, less $12M of higher regional corporate costs ($104M).

- FINANCIAL SERVICES IS NOW A BANK: total loans disbursed a record $1.2B (+72%); gross loan portfolio $2.3B, +197% from $781M (still doubled excluding Superbank, consolidated from June 2026); customer deposits $2.5B across GXS Bank (Singapore), GXBank (Malaysia) and Superbank (Indonesia). The release names higher net impairment losses on financial assets, mainly Digibank expected credit losses, as a reason operating profit did not improve more. Stash Financial was acquired 100% in July 2026 and consolidates into Financial Services from Q3.

- BALANCE SHEET: gross cash liquidity $7.4B (from $6.9B at March 31), net cash liquidity $5.4B (from $5.0B) - more than a third of the $15.0B market capitalisation. $1.5B of convertible notes outstanding, whose conversion feature is carried as a derivative and remeasured each period. Caveat: $2.5B of the gross cash is digibank customer deposits, so cash genuinely available for repurchases is materially below the headline.

- SHARE COUNT: 3,969,290,878 Class A + 128,355,800 Class B = 4,097,646,678 shares (FY2025 20-F cover page). Both classes are economically identical; Class B is super-voting only. Several data providers publish a market capitalisation on the Class A count alone (~$14.5B); the correct figure at $3.67 is ~$15.0B. Grab is a foreign private issuer: it files 6-K / 20-F, not 10-Q / 10-K, and reports under IFRS.

What to watch: Bullish: adjusted free cash flow reconverging with adjusted EBITDA over the next two quarters, or Financial Services crossing into positive segment EBITDA (it improved from -$26M to -$15M). Bearish: a rising net-impairment line as the tripled loan book seasons, or the Mobility take rate falling another 50bps - which would say the incentive spend is structural rather than a fuel-crisis response.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

ON Semiconductor Corporation (onsemi) (ON) Q2 2026 — Reported August 3, 2026 before the open for Q2 2026 (the quarter ended July 3, 2026). Revenue $1,603.5M (+9.2% YoY, +6.0% QoQ) vs ~$1.59B expected. Non-GAAP EPS $0.74 (+39.6%) vs ~$0.715 expected; GAAP EPS $0.56. Non-GAAP gross margin 39.3% (+170bps), non-GAAP operating margin 20.8%. Free cash flow $425.4M, quadruple last year's $106.1M. $332M of buybacks. Q3 guide: revenue $1,650-1,750M, non-GAAP gross margin 40.0-42.0%, non-GAAP EPS $0.81-0.93. Shares closed the regular session at $80.40 (-1.5%) and traded up about 5% after hours to roughly $84.38. The stock is still ~40% below its June 3 close of $133.93.

The line nobody printed: onsemi's nine percent revenue growth came almost entirely from one segment. Power Solutions grew 19%, but Analog and Mixed-Signal - a third of the company - SHRANK 2%, and automotive, at 49% of revenue, grew only 6.6%. Two-thirds of onsemi compounded in the mid single digits. And the free cash flow that quadrupled was made with capex of $34.3M in the quarter - $171.6M over the trailing twelve months, under 3% of revenue, for a company that owns its own fabs. Normalise capex to 8% and trailing free cash flow is ~$1.18B, not $1.50B. Meanwhile the Synaptics deal issues ~53M new shares, undoing roughly four years of buybacks.

THE CALL: HOLD (3/5, AN EXCELLENT QUARTER AT A DEMANDING PRICE) — base-case value ~$68.0 vs ~$80.4 today.

KEY METRICS:

- CALL: HOLD 3/5 - fair value ~$68 vs the $80.40 close (-15%), and ~19% below the $84.38 after-hours print. DCF on free cash flow with capex NORMALISED: revenue $6.6B (2026E) compounding to $10.4B by 2031, FCF margin ramping 17% -> 20% as capex normalises to ~8% of revenue. FCF $1.27B (2027) rising to $2.08B (2031). At a 10% discount rate and 3% terminal growth: PV of 2027-2031 FCF $6.26B + PV of terminal value $19.04B = EV $25.30B, less ~$0.59B net debt, / 397M non-GAAP diluted shares = $62/sh. Bear $34, bull $89, prob-weighted 25/50/25 = $62. We sit at $68, above the weighted case, for AI-data-center optionality and Synaptics being modestly accretive to gross margin.

- REVERSE DCF: at $80.40 the enterprise value is ~$32.5B. At a 10% discount rate with 3% terminal growth that price demands ~$2.28B of steady free cash flow starting NOW - against ~$1.18B on a normalised-capex basis today. Our base case does not reach $2.28B until after 2031.

- STREET: Buy - 24 buy / 22 hold / 1 sell (47 analysts), consensus target $116.13, median $117.50, range $75-$150, about +44% vs the $80.40 close. Recent published targets: Susquehanna $150 (Positive), Wells Fargo $130 (Overweight), Mizuho $125 (Outperform), TD Cowen $95 (Hold). We DIFFER on the rating and are far more CAUTIOUS on the number. The gap is almost entirely the capex assumption and how much automotive recovery you underwrite in advance.

- THE PRINT: revenue $1,603.5M (+9.2% YoY, +6.0% QoQ). GAAP gross margin 38.4% / non-GAAP 39.3% (from 37.6%). GAAP operating margin 16.1% / non-GAAP 20.8% (from 17.3%). GAAP net income $226.8M and EPS $0.56; non-GAAP net income $293.8M and EPS $0.74 (from $0.53). R&D $140.8M, essentially flat YoY. Restructuring and asset impairments $41.2M this quarter, against $329.3M in Q1 2026. Management: revenue, gross margin and EPS all above the midpoint of guidance, and 'year-over-year EPS grew four times faster than revenue'.

- SEGMENTS: PSG (Power Solutions) $829.0M, +19% YoY and +13% QoQ - nearly all of the growth. AMG (Analog and Mixed-Signal) $545.7M, -2% YoY, driven by an $11.5M decline in the industrial end-market. ISG (Intelligent Sensing) $228.8M, +7% YoY but -3% QoQ.

- END MARKETS (from the 10-Q): Automotive $781.3M vs $733.2M, +6.6% - 49% of revenue. Industrial $422.7M vs $406.2M, +4.1%. Other (computing incl. AI data center, consumer, networking) $399.5M vs $329.3M, +21.3%. Management now expects AI data center revenue to MORE THAN DOUBLE in 2026, but has not disclosed the dollar base.

- CASH: operating cash flow $459.7M (+150% YoY), capex $34.3M, free cash flow $425.4M vs $106.1M - FCF margin 26.5% vs 7.2%. TTM: operating cash flow $1,672.0M, capex $171.6M (2.8% of $6,197.8M revenue), free cash flow $1,500.4M. That capex ratio is a TROUGH, not a run rate, for a company that runs its own fabs.

- BALANCE SHEET (July 3, 2026): cash $3,514.5M + short-term investments $350.0M. Debt $4,459.4M carrying ($802.1M now CURRENT as the 0% converts due 2027 rolled over, $3,657.3M long-term); total principal $4,504.9M per the 10-Q. Net debt ~$595M. Inventory $2,047.5M, flat sequentially. Stockholders' equity $7,218.7M. Buybacks $332M in the quarter; YTD shareholder returns ~105% of free cash flow. GAAP diluted shares 404.4M (from 414.9M); non-GAAP diluted 397.0M. Shares outstanding 389,311,721 at July 29, 2026 (10-Q cover).

- GUIDANCE (Q3 2026): revenue $1,650-1,750M (midpoint $1.70B, +6% sequentially). GAAP gross margin 39.9-41.9% / non-GAAP 40.0-42.0%. Operating expenses $318-333M GAAP / $303-318M non-GAAP. Other income and expense -$18M. GAAP EPS $0.79-0.91 / non-GAAP EPS $0.81-0.93 on 395M non-GAAP diluted shares. Midpoint $0.87 implies ~$1.61 of 2H non-GAAP EPS against $1.38 in 1H.

- SYNAPTICS: announced June 25, 2026 - onsemi's largest acquisition ever, ~$7B all-stock, 1.350 onsemi shares per Synaptics share (~19% premium to the 10-day VWAP). Synaptics holders would own ~12% of the combined company (~53M new onsemi shares). Expected to close mid-2027. HSR filed July 17, 2026. Break fees: $235M payable by Synaptics, $320M payable by onsemi on an antitrust failure. ON closed down roughly 24% the session the deal hit ($118.74 -> $90.65).

- STRUCTURE: ON Semiconductor Corporation, branded onsemi, Nasdaq: ON, CIK 0001097864, headquartered in Scottsdale, Arizona. CEO Hassane El-Khoury, CFO Thad Trent. Fiscal quarters are 13-week periods - Q2 2026 ENDED JULY 3, 2026, not June 30. Three segments: PSG, AMG, ISG.

What to watch: Bullish: automotive revenue accelerating above +10% YoY, or management putting a dollar figure on the AI data center business rather than a growth rate. Bearish: another quarter of AMG shrinking, capex stepping back above 8% of revenue without a revenue response, or the Synaptics deal hitting a genuine antitrust problem.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Jazz Pharmaceuticals plc (JAZZ) Q2 2026 — Reported after the close on August 3 (three months ended June 30, 2026). Total revenue $1,208.3M, +15.6%, a company record and ~$94M above consensus. GAAP gross margin 90.4%. GAAP diluted EPS $2.78 (from -$11.74). Non-GAAP adjusted EPS $5.71 vs $6.18 expected — but the entire shortfall is $77.0M of acquired IPR&D ($0.94/share after tax) that Jazz, unlike most of pharma, does NOT add back; ex-IPR&D adjusted EPS was $6.65, a 47-cent BEAT. 2026 revenue guidance RAISED to $4.60-4.75B from $4.25-4.50B. The stock closed at $251.58, up 118% in twelve months, and traded $256 after hours.

The headline said Jazz missed. It did not. The $0.47 shortfall is one line: $77.0M of acquired in-process R&D — upfront payments to AbCellera and Werewolf Therapeutics — which Jazz leaves inside BOTH GAAP and adjusted earnings while most peers strip it out. Add it back and adjusted EPS was $6.65 against $6.18 expected. Meanwhile the patent cliff everyone prices this stock for has already happened (Xyrem is down to $30.5M a quarter) and the next one is contracted away: all ten Epidiolex generic filers are settled and licensed to launch in the very late 2030s.

THE CALL: BUY (4/5, A COMPANY GROWING 16% AND PRICED FOR ZERO GROWTH, FOREVER) — base-case value ~$280.0 vs ~$251.58 today.

KEY METRICS:

- THE CALL: BUY 4/5 - fair value ~$280 vs the $251.58 close (+11%); Street consensus Buy (43 buy / 5 hold / 0 sell, 48 ratings on file) with an average target of $266.55 (range $229-$307, median $260), only +6%. We AGREE on the rating and are modestly more BULLISH on the number. Note the oddity: a near-unanimous Buy with a target 6% above spot is a Hold wearing a Buy's clothing.

- DCF GRID (bear/base/bull x 8/9/10%): $214-187-165, $304-261-228, $396-334-287. Probability-weighted 25/50/25 gives $261 at 9% and $305 at 8%; we sit at $280 on an 8.5% rate (0.36 beta, a decade of contracted exclusivity). Base case: 2026 owner earnings ~$1.30B (adjusted net income less stock comp after tax less net capex; cross-checks to 1H26 operating cash flow of $823.9M) growing 8/7/6/5/4%, 1.0% terminal. REVERSE DCF: at $251.58 the enterprise is priced at $18.53B, which at 8% with 1% terminal growth demands ~$1.30B of owner earnings FLAT FOREVER - exactly what Jazz earns today. The market is paying for zero growth in perpetuity.

- THE PRINT: total revenue $1,208.3M (+15.6%, a record) vs ~$1,114M consensus; net product sales $1,156.1M (+17.3%); GAAP gross margin 90.4% (vs 88.9%); GAAP operating income $248.2M (vs -$686.4M); GAAP diluted EPS $2.78 (vs -$11.74); non-GAAP adjusted EPS $5.71 (vs -$8.25); acquired IPR&D $77.0M in BOTH measures. Diluted shares 61.2M to 69.4M (+13%) as the exchangeables came into the money at $153.05.

- BY MEDICINE (Q2 2026 / Q2 2025): Xywav $471.2M / $415.3M (+13.5%, ~525 net patient adds, ~17,125 active patients: 11,275 narcolepsy + 5,850 IH). Epidiolex/Epidyolex $292.1M / $251.7M (+16.0%). Zepzelca $105.8M / $74.5M (+42.0%). Rylaze/Enrylaze $99.5M / $100.7M (-1.2%). Defitelio $62.0M / $48.1M (+28.9%). Modeyso $48.2M / $0.5M. Vyxeos $31.4M / $44.9M (-30.1%). Xyrem $30.5M / $35.4M (-13.8%). Ziihera $15.4M / $6.0M. Franchises: Sleep $501.7M (41.5% of revenue, down from 43.1%), Epilepsy $292.1M, Oncology $362.3M (+31.9%).

- THE ADJUSTMENT BRIDGE, INTERROGATED: GAAP $2.78 to non-GAAP $5.71 is a $2.93/share gap. Intangible amortisation $170.0M ($2.45/sh) is 84% of the gross add-back - and it is the amortisation of assets Jazz BOUGHT (Epidiolex from GW, Ziihera from Zymeworks, Modeyso from Chimerix), i.e. the deferred purchase price of the revenue being reported. Plus share comp $73.3M ($1.06), inventory step-up $16.6M ($0.24), less tax effect -$56.3M. Acquired IPR&D is NOT added back.

- THE CLIFF IS BEHIND THEM: all ten Epidiolex ANDA filers (Teva, Padagis, Apotex, InvaGen, Lupin, Taro, Zenara, MSN, Alkem, Ascent) are SETTLED and licensed to launch in the very late 2030s. Xyrem, once a ~$2B franchise, is down to $30.5M a quarter and the high-sodium authorised-generic royalty fell 22% to $42.2M - that cliff already happened and revenue still grew 16%. BALANCE SHEET: repaid $1.0B of 2.00% exchangeables IN CASH at maturity on June 15 (plus 1,890,193 shares for the conversion premium); debt principal $5.4B to $4.4B ($1.9B term loans, $1.5B 4.375% secured notes due 2029, $1.0B 3.125% exchangeables due 2030); cash and investments $2.20B; $885M undrawn revolver; net debt ~$2.2B (~1.0x). NO shares repurchased in 1H26 ($225M still authorised) vs $125.0M in 1H25.

- WHAT WE DO NOT LIKE: zero buyback against a 13% rise in diluted shares; $170M a quarter of amortising purchased revenue; Zepzelca grew 42% but Jazz will file in 3Q26, in alignment with FDA, to REMOVE the second-line indication entirely after the LAGOON trial (first-line maintenance unaffected); Vyxeos -30% and Rylaze -1.2%; Xywav concentration at ~41% of net product sales against a live competitor in Avadel; MFN/IRA drug-pricing pressure.

What to watch: Bullish: FDA approval of zanidatamab in 1L HER2+ gastroesophageal adenocarcinoma on or before the August 25 PDUFA date (a far larger population than Ziihera's current biliary-tract indication, and essentially none of it is in guidance); the second interim HERIZON-GEA-01 overall-survival readout in 3Q26; Xywav net patient adds holding above 500 a quarter; the buyback restarting. Get the first and third and we move toward $330. Bearish: Xywav net adds below ~400 (Avadel taking share); a 2027 revenue guide that does not start with a five; a complete response letter on August 25; another large acquired-IPR&D quarter without a matching asset. Any two and we are nearer $190.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Powell Industries, Inc. (POWL) Q3 FY2026 — Reported after the close on August 3 (the 8-K hit EDGAR at 4:28pm ET; fiscal Q3 2026, the three months ended June 30, 2026). Revenue $311.7M, +8.9%. Diluted EPS $1.42 vs $1.32. New orders a record $934M, +158%, a 3.0x book-to-bill. Backlog $2.4B, +69% y/y and +35% sequentially. Cash and short-term investments $633.6M with no debt. The stock closed at $219.72, up 5.3% into the print and up 189% in twelve months — but 32% below its May 11 high of $322.05.

The number nobody decomposed: Powell says in the same release that it booked THREE mega orders — one data center order above $400M, one petrochemical order of ~$75M, one LNG order of ~$60M. That is at least $535M, or 57% of the record $934M. Strip them out and the rest of the order book was roughly $399M against $362M a year ago — up about 10%, not 158%.

THE CALL: SELL (3/5, A GREAT BUSINESS AND A REAL BACKLOG — AT A PRICE ABOVE OUR BULL CASE) — base-case value ~$140.0 vs ~$219.72 today.

KEY METRICS:

- THE CALL: SELL 3/5 - fair value ~$140 vs the $219.72 close (-36%). Street is Hold (3 buy / 6 hold / 1 sell, ~10 analysts) with a ~$288 median target (panels span $259-$316, +31%), so we DIFFER on the rating and are far more CAUTIOUS on the number.

- DCF GRID (bear/base/bull x 9/10/11%): $86-83-80, $134-129-124, $214-205-197. Probability-weighted 25/50/25 gives $136 at 10% and $142 at 9%; we sit at $140 because a debt-free balance sheet with $634M of cash deserves it. NOTE: at $219.72 the stock trades ABOVE our bull case. REVERSE DCF: backing out the $634M of cash, the operating business is priced at $7.41B, which at a 10% discount rate and an 18x exit multiple demands FY2031 operating income of ~$586M - roughly $3.3B of revenue at an 18% margin, a 22% revenue CAGR for five straight years, from a company that just grew 9%.

- THE THROUGH-CYCLE MARGIN, which drives everything: Powell earns a 19.7% operating margin on a TTM basis and earned 17.7% in FY2024. Across FY2018-FY2022 it averaged 1.2% (-2.0%, 2.2%, 4.0%, 0.2%, 1.4%). Gross margin was 16.0% as recently as FY2022 and is 30.6% now. We assume 15.5% forever - thirteen times the prior five-year average.

- THE PRINT: revenue $311.7M (+8.9% y/y, +5.1% q/q); gross profit $95.3M at 30.6% (vs 30.7%); operating income $64.1M at 20.6% (vs 21.0% - it FELL); net income $52.2M; diluted EPS $1.42 (vs $1.32); 36.6M diluted shares. Nine months: revenue $859.5M, EPS $3.81. A 3-for-1 forward split was effected April 2, 2026.

- THE ORDER BOOK, DECOMPOSED: $934M booked. Three mega orders (Powell defines mega as >$50M): >$400M data center (behind-the-meter design of on-site generation assets), ~$75M petrochemical (fertilizer), ~$60M LNG (US Gulf Coast). That is 57% of the record from three contracts; everything else was ~$399M vs $362M a year ago, about +10%. By end market on revenue: Commercial and Other Industrial +54%, Electric Utility +18%, Petrochemical -49%.

- THE THROUGHPUT GAP: backlog +69% while revenue grew +9%, so coverage stretched from 1.30x trailing revenue to 2.07x - the backlog is lengthening, not converting. Nine-month capex was $10.4M, DOWN 8.7% from $11.4M and just 1.2% of revenue, with greenfield still only being 'evaluated'. Revenue grew 44.8% in FY2024, then 9.1% in FY2025, then ~7% this year. The CFO guided gross margin 'consistent to the trailing twelve months' - TTM is ~30.1% against a 30.6% print, i.e. flat to slightly down. Incremental operating margin on the year-over-year growth was 15.5%.

- THE BALANCE SHEET (genuinely excellent): cash and short-term investments $633.6M, up $158.0M in nine months, against essentially no debt (deferred and other long-term liabilities $25.9M). Working capital is $606.5M but EXCLUDING cash it is NEGATIVE $27.0M - it was positive $9.8M at fiscal year end - because customer progress payments fund the growth. ROIC 24.1%, ROE 29.2%. Interest income of $5.0M is 7.3% of pre-tax profit. Quarterly dividend $0.09.

What to watch: Bullish: quarterly revenue above $360M (proving the factory can accelerate); capex above 3% of revenue (greenfield actually under construction); gross margin holding above 31%. All three and we move toward $200. Bearish: bookings below $400M in a quarter without a mega order; gross margin below 29%; any cancellation or scope reduction on a mega order. Any two and we are nearer $90.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Diamondback Energy, Inc. (FANG) Q2 2026 — Reported after the close on August 3 (three months ended June 30, 2026). Total revenue $5,562M, +51.2%. GAAP diluted EPS $6.65 vs $2.38 a year ago; adjusted EPS $6.48 vs a ~$6.40 consensus. Free cash flow $2,330M on capex of $996M. Production crossed 1,018 MBOE/d — above one million barrels of oil equivalent per day for the first time in company history — on a realized oil price of $96.82/bbl after the Strait of Hormuz supply shock. Full-year guidance RAISED twice (oil to 522+ MBO/d, total to 1,000+ MBOE/d) with capex unchanged at $3.90B. The stock closed at $198.75 the session INTO the print, down 2.1%; there is no reaction session yet.

The number nobody decomposed: 525 MBO/d x 91 days x $96.82 realized = $4,626M of oil sales, against $4,786M of TOTAL wellhead revenue. So gas and NGLs together contributed about $160M — 3.4% of the revenue from roughly 48% of the molecules. Diamondback's realized natural gas price was NEGATIVE $2.15/Mcf; Waha touched about -$10/Mcf in the quarter. The 1 million BOE/d milestone is half revenue and half disposal problem.

THE CALL: AVOID (2/5, A MAGNIFICENT QUARTER, PRICED AS IF THE WAR PREMIUM IS PERMANENT) — base-case value ~$136.0 vs ~$198.75 today.

KEY METRICS:

- THE CALL: AVOID 2/5 - fair value ~$136 vs the $198.75 close (-32%); Street average $219.91, median $232 (48 buy / 5 hold / 0 sell, 53 analysts, range $100-$255, +11%), so we DIFFER on the rating and are far more CAUTIOUS on the number. We would be real buyers near $110.

- DCF GRID (bear/base/bull x 8.5/9.5/10.5%): $102-91-80, $150-136-123, $197-182-166. Scenarios are OIL PRICES, stated on the slide: bear mid-cycle WTI $62 ($3.2B attributable FCF), base $75 ($5.0B), bull $88 ($6.8B). Base case: $5.0B attributable FCF capitalised over 12 years of visible inventory at 9.5% = $34.9B, plus $14.0B residual (Viper royalty, deeper zones, surface power), less $10.7B standalone net debt, over 280.6M shares = ~$136. CROSS-CHECK: at $136 that is 4.9x mid-cycle attributable EBITDA versus 6.5x at the market price. REVERSE DCF: at $198.75 the attributable enterprise is $66.4B; strip the residual and the remaining $52.4B demands ~$7.5B of attributable FCF a year for twelve years, which at ~$134M per $1/bbl requires roughly $93/bbl WTI PERMANENTLY - within four dollars of the war-shocked $96.82 just realized.

- THE PRINT: total revenue $5,562M (+51.2% from $3,678M); oil, gas and NGL sales $4,786M; net income attributable $1,882M vs $699M (+169%); GAAP diluted EPS $6.65 vs $2.38; adjusted EPS $6.48 vs ~$6.40 consensus; consolidated adjusted EBITDA $3,940M ($3,549M attributable); operating cash flow $3,589M; capex $996M; FREE CASH FLOW $2,330M. Diluted shares 281,202K; 280,567,508 outstanding at June 30.

- PRODUCTION AND UNIT ECONOMICS: oil 525 MBO/d (top end of guidance), total 1,018 MBOE/d - above 1.0 million BOE/d for the first time ever. Realized prices: oil $96.82/bbl (vs $73.47 in Q1 and $63.23 a year ago), natural gas NEGATIVE $2.15/Mcf (vs +$0.18 and +$0.88), NGLs $18.56/bbl, combined $51.68/BOE. Cash costs $10.96/BOE (LOE $5.96, production and ad valorem taxes $3.26, gathering and transport $1.22, cash G&A $0.52), DOWN from $11.26 in Q1. Capex $10.75/BOE; free cash flow $25.15/BOE.

- CAPITAL ALLOCATION - THE FORMULA IS GONE: total return of capital $452M (base dividend $1.10/share plus $141M of buybacks at $186.63) = just 19.4% of the $2,330M of free cash flow. Total debt cut $1,302M in the quarter to $12,766M; net debt down $1,590M to $12,304M and down $2.8B (-19%) over twelve months. The company states it 'removed our prior formulaic return of capital framework' to accelerate debt reduction. The board DOUBLED the buyback authorization to $16.0B on July 30 with $9.9B remaining - while spending only 6% of quarterly FCF on stock. Cumulative buyback: 43.0M shares for $6,124M at an average of $142.44.

- THE HEDGE BOOK AND THE MACRO: as of July 31 Diamondback held LONG PUTS (floors only, no ceiling) on ~305 MBO/d - 190,000 b/d WTI Cushing at $52.57, 95,000 b/d Magellan East Houston at $50.53, 20,000 b/d Brent at $52.50. Hedged oil realization $94.33 vs $96.82 unhedged = a $2.49/bbl cost, roughly $119M in the quarter, insuring against $50 oil. Management's own letter calls the Strait of Hormuz disruption 'the largest supply shock in the history of the global oil market', with May global production 13.6 MMbbl/d below pre-conflict levels and inventory draws of 143 MMbbl in May alone (IEA).

- GUIDANCE AND THE FORWARD OPTIONS: FY2026 oil raised to 522+ MBO/d (from 520+) and total to 1,000+ MBOE/d (from 972+), capex UNCHANGED at ~$3.90B. Q3 oil 517-527 MBO/d (995-1,015 MBOE/d), Q3 capex $950-1,050M. Waha gas turned POSITIVE in July after a record ~-$10/Mcf; long-haul takeaway expected to MORE THAN DOUBLE by year end. Diamondback is working to land gigawatt-plus scale behind-the-meter power projects on its own surface acreage, with a large shovel-ready project awaiting a signed long-term contract. Operationally: longest well in company history at 31,465 ft, first six U-turn (3-mile) laterals, equipment cost per well -14% QoQ, flaring -24% QoQ.

What to watch: Bullish: WTI holding above $85 into 2027 (drags the base case toward $180); a SIGNED gigawatt-scale power contract on Diamondback's own surface acreage, which converts negatively-priced Permian gas into contracted revenue and is in nobody's model; Waha basis staying positive as the doubled long-haul takeaway arrives. Bearish: another quarter with the payout under 30% of free cash flow (if management will not buy stock here with $9.9B authorised, that is the tell); WTI back under $75 while service inflation hits in 2027; any slippage in the takeaway build that puts Waha back through zero. Any two and our number is nearer $110.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.